Lixte Biotechnology Holdings Inc (LIXT)
Official siteBIOTECHNOLOGY
Last updated: Jul 02, 2026 at 5:00 PM ET
Lixte Biotechnology Holdings Inc (LIXT) Financials: Revenue, Profit and Cash Flow
Lixte Biotechnology Holdings reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$6.01M, operating cash flow was -$3.07M and free cash flow was -$3.07M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$1.92M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $5.11M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $254.92K | $726.23K | $898.10K | $1.35M | $1.74M | $1.22M | $820.91K | $40.70K | $467.26K | $1.30M |
| Operating income | -$5.11M | -$3.57M | -$5.09M | -$6.31M | -$6.72M | -$3.27M | -$2.49M | -$2.14M | -$1.81M | -$2.13M |
| Net income | -$6.01M | -$3.59M | -$5.09M | -$6.31M | -$6.73M | -$3.26M | -$2.39M | -$2.13M | -$1.81M | -$2.13M |
| EBITDA | N/A | -$3.57M | -$5.07M | -$6.30M | N/A | -$3.26M | -$2.49M | -$2.13M | -$1.81M | -$2.13M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$1.99M | -$1.82M | -$1.80M | -$774.81K | -$706.94K | -$613.50K | -$983.26K | -$1.01M | -$966.88K | -$1.03M | -$1.02M | -$1.67M |
| Net income | -$1.92M | -$2.54M | -$2.03M | -$775.67K | -$709.55K | -$617.69K | -$986.03K | -$1.01M | -$971.32K | -$1.03M | -$1.02M | -$1.67M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $664.49K by $4.44M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $12.73M | $1.15M | $4.31M | $5.56M | $5.09M | $5.23M | $2.67M | $4.34M | $1.37M | $433.41K |
| Current assets | $5.18M | $1.04M | $4.23M | $5.56M | $5.09M | $5.23M | $2.67M | $4.33M | $1.37M | $433.41K |
| Cash and equivalents | $5.11M | $1.04M | $4.20M | $5.35M | $4.82M | $5.07M | $2.60M | $4.27M | $1.31M | $199.93K |
| Total liabilities | $1.77M | $318.28K | $313.86K | $394.79K | $302.93K | $216.52K | $237.90K | $210.91K | $373.02K | $218.65K |
| Short-term debt | $664.49K | N/A | $313.86K | $394.79K | $302.93K | N/A | $237.90K | $210.91K | $60.99K | $59.06K |
| Shareholder equity | $9.66M | $827.22K | $3.99M | $5.17M | $4.79M | $5.01M | $2.43M | $4.13M | $995.04K | $214.76K |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10.87M | $12.73M | $5.43M | $1.19M | $1.51M | $1.15M | $1.70M | $2.67M | $3.59M | $4.31M | $5.23M | $3.10M |
| Total liabilities | $1.69M | $1.77M | $521.42K | $537.12K | $355.10K | $318.28K | $328.96K | $421.46K | $462.84K | $313.86K | $311.74K | $402.61K |
| Cash and equivalents | $3.25M | $5.11M | $2.89M | $887.21K | $1.38M | $1.04M | $1.64M | $2.60M | $3.41M | $4.20M | $5.11M | $2.91M |
| Shareholder equity | $7.95M | $9.66M | $4.91M | $651.46K | $1.16M | $827.22K | $1.37M | $2.25M | $3.13M | $3.99M | $4.92M | $2.69M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.07M | -$3.16M | -$4.29M | -$4.61M | -$4.14M | -$2.13M | -$1.67M | -$1.51M | -$1.41M | -$1.68M |
| Capital expenditures | $0 | $4 | $5 | $3 | $5 | $4 | $0 | $0 | $0 | $0 |
| Free cash flow | -$3.07M | -$3.16M | -$4.29M | -$4.61M | -$4.14M | -$2.13M | -$1.67M | -$1.51M | -$1.41M | -$1.68M |
| Dividends paid | $69.07M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.00K |
| Investing cash flow | -$3.17M | N/A | N/A | $5.14M | N/A | N/A | N/A | N/A | N/A | $104.09K |
| Financing cash flow | $10.31M | $0 | $3.14M | $5.14M | $3.90M | $4.60M | $4.60M | $4.48M | $2.52M | $1.75M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.83M | -$1.09M | -$926.75K | -$487.49K | -$568.48K | -$598.67K | -$957.60K | -$819.04K | -$789.23K | -$902.12K | -$944.39K | -$1.18M |
| Capital expenditures | $24.86K | $3 | $2 | $5 | $3 | $0 | $5 | $0 | $0 | $3 | $0 | $4 |
| Free cash flow | -$1.86M | -$1.09M | -$926.75K | -$487.49K | -$568.49K | -$598.67K | -$957.60K | -$819.04K | -$789.23K | -$902.13K | -$944.39K | -$1.18M |
Frequently Asked Questions About LIXT
What is Lixte Biotechnology Holdings' annual revenue?
Lixte Biotechnology Holdings reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Lixte Biotechnology Holdings profitable?
No. Lixte Biotechnology Holdings reported net income of -$6.01M for the fiscal year ended Dec 31, 2025.
How much free cash flow does LIXT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$3.07M minus capital expenditures of $0 produced free cash flow of -$3.07M.
How much debt does Lixte Biotechnology Holdings have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $664.49K and cash and equivalents of $5.11M.
LIXT pages: Overview, Financials